Repros Therapeutics, Inc. (NASDAQ: RPRX)

Repros Therapeutics, Inc. (NASDAQ: RPRX) is focused on developing oral small molecule drugs to treat substantial, but unmet medical needs. The company has a proven track-record of rapidly progressing their therapeutic candidates through clinical development with efficiency. Proellex, the company’s lead drug, selectively blocks the progesterone receptor and may treat uterine fibroids, endometriosis and anemia associated with uterine fibroids. For further information, visit the Company’s web site at www.reprosrx.com.